Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Up 91.5% in September

Sysmex Corporation ADR (OTCMKTS:SSMXY) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 11,300 shares, an increase of 91.5% from the August 31st total of 5,900 shares. Based on an average daily trading volume, of 508,500 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 508,500 shares, the short-interest ratio is currently 0.0 days.

Sysmex Price Performance

OTCMKTS SSMXY opened at $12.70 on Tuesday. The company has a market capitalization of $7.99 billion, a PE ratio of 25.40 and a beta of 1.16. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.49 and a current ratio of 3.37. The business’s fifty day moving average is $13.40 and its 200 day moving average is $16.12. Sysmex has a fifty-two week low of $11.93 and a fifty-two week high of $22.00.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Wednesday, August 6th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). The company had revenue of $717.09 million for the quarter, compared to analysts’ expectations of $807.27 million. Sysmex had a net margin of 9.35% and a return on equity of 10.20%. Sell-side analysts predict that Sysmex will post 0.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Sysmex from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.